Sandoz Partners with mAbxience to Develop Emicizumab Biosimilar
Sandoz has entered into an agreement with mAbxience for the development, manufacturing and commercialisation of a proposed emicizumab biosimilar candidate. The reference drug is Hemlibra (emicizumab), used in treating haemophilia A, which had estimated global sales of $5.7 billion. Under the deal, mAbxience will handle development at its GMP-approved facilities in Argentina and Spain, while Sandoz gains exclusive commercialisation rights globally except for certain Latin American countries. This partnership marks the first hematology-focused biosimilar candidate in Sandoz's pipeline and expands mAbxience’s rare disease portfolio. Haemophilia A affects 80% of haemophilia cases worldwide due to a deficiency or defect in factor VIII, a clotting protein. The collaboration aims to increase patient access to high-quality biologic treatments through combined development expertise and global distribution capabilities. mAbxience is majority-owned by Fresenius Kabi and partially owned by Insud Pharma. It operates across more than 100 markets with over 40 partners, focusing on biosimilars in various therapeutic areas including oncology and immunology.
Topics: biosimilar Hemlibra hemophilia A mAbxience Sandoz